SURGICAL TREATMENT STRATEGY FOR STOMACH CANCER
Abstract
This article examines contemporary surgical treatment strategies for stomach cancer within the framework of multidisciplinary oncologic management. The paper analyzes the role of surgery as the primary curative modality for resectable gastric cancer, emphasizing the importance of achieving R0 resection and adequate lymphadenectomy for accurate staging and improved survival outcomes. Various surgical approaches—including distal, total, and proximal gastrectomy—are discussed in relation to tumor localization, disease stage, and patient-specific factors. The study also highlights the evolution of minimally invasive techniques such as laparoscopic and robotic-assisted gastrectomy, outlining their clinical benefits and oncological safety. Furthermore, the integration of perioperative chemotherapy, enhanced recovery protocols, and personalized treatment planning is evaluated as essential components of modern surgical strategy. The findings underscore that optimal outcomes in stomach cancer management require evidence-based surgical decision-making, multidisciplinary collaboration, and continuous technological advancement.
References
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2020). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 70(4), 313–331.
2. Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. T., & Lordick, F. (2020). Gastric cancer. The Lancet, 396(10251), 635–648.
3. Japanese Gastric Cancer Association. (2021). Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer, 24(1), 1–21.
4. National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2023.
5. Ajani, J. A., D’Amico, T. A., Bentrem, D. J., et al. (2017). Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 15(3), 298–329.
6. Cunningham, D., Allum, W. H., Stenning, S. P., et al. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England Journal of Medicine, 355(1), 11–20.
7. Al-Batran, S. E., Hofheinz, R. D., Pauligk, C., et al. (2019). Perioperative chemotherapy with FLOT versus ECF/ECX for resectable gastric or gastro-esophageal junction adenocarcinoma (FLOT4 trial). The Lancet, 393(10184), 1948–1957.
8. Songun, I., Putter, H., Kranenbarg, E. M., Sasako, M., & van de Velde, C. J. H. (2010). Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. The Lancet Oncology, 11(5), 439–449.
9. Kitano, S., Shiraishi, N., Uyama, I., Sugihara, K., & Tanigawa, N. (2007). A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Annals of Surgery, 245(1), 68–72.
10. Hyung, W. J., Yang, H. K., Park, Y. K., et al. (2020). Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: The KLASS-02 randomized clinical trial. Journal of Clinical Oncology, 38(28), 3304–3313.
11. Strong, V. E., Russo, A., Yoon, S. S., et al. (2009). Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Annals of Surgery, 251(4), 640–646.
12. Degiuli, M., Sasako, M., Ponti, A., et al. (2014). Randomized clinical trial comparing survival after D1 versus D2 gastrectomy for gastric cancer. British Journal of Surgery, 101(2), 23–31.
